Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
M Hallek, O Al‐Sawaf - American journal of hematology, 2021 - Wiley Online Library
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
[HTML][HTML] Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
[HTML][HTML] Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia
Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
TD Shanafelt, XV Wang, CA Hanson… - Blood, The Journal …, 2022 - ashpublications.org
Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …
Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
Abstract Background Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled …
Background Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with
efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …
efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …